Latest Developments in Cell and Gene Therapy Manufacturing Cell and gene therapies are rapidly emerging as one of the most transformative areas in modern medicine. These advanced therapies aim t...
Key Highlights: Implications: GTBL’s MicroBiopharm acquisition is a strategic move to become a more integrated, higher-value pharma services and ingredients player. The mai...
Key Highlights: Implications: The merger gives HAB Pharma a bigger scale story: a cleaner corporate structure, more manufacturing capacity, and a stronger platform to sell specialty products in more ...
Key Highlights: Implications: Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers...
Key Highlights: Implications: AstraZeneca India is partnering with Telangana to embed Qure.ai’s chest X‑ray AI into routine workflows at about 20 public facilities, turning basic radiography into a lu...
Key Highlights: Implications: Biocon is consolidating leadership under Shreehas Tambe to drive its newly integrated biosimilars–generics platform, with a clear focus on...
Key Highlights: Implications: The new indication firmly positions durvalumab as a frontline immunotherapy option in advanced liver cancer, giving oncologists a more con...
Key Highlights: Implications: Oncology ace Vanneste turbocharges MSD’s immuno-oncology push against Roche/Pfizer, targeting India’s exploding cancer caseload with ke...
Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
